PSA-DETECTED PROSTATE-CANCER - CONTRASTS WITH PALPABLE DISEASE

被引:8
作者
MATTHEWS, GJ [1 ]
FRACCHIA, JA [1 ]
机构
[1] LENOX HILL HOSP,DIV UROL,NEW YORK,NY 10021
关键词
PSA; PROSTATE CANCER; T1C; TB;
D O I
10.1002/jso.2930590108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical and pathologic characteristics of 100 consecutive men with clinically localized prostate cancer and staged by radical prostatectomy were reviewed. Men with impalpable prostate-specific antigen (PSA) detected cancers (T1c) were contrasted against men with palpable disease (TB). Lesions were clinically staged as T1c in 53 men and TB in 47 men. Mean serum PSA for men with Tie cancers was 11.8 +/- 0.7 ng/dL (normal: 0 > 4) and 14.1 +/- 1.7 ng/dL for men with TB disease. Histologic evaluation revealed a mean Gleason's sum of 6.4 +/- 0.2 (scale: 2 > 10) for T1c lesions and 6.6 +/- 0.2 for men with TB cancers (P = NS). DNA content was diploid in 67% of T1c cancers and 62% of TB lesions (P = NS). An overall 43% clinical staging error was observed. Extraprostatic extension was demonstrated in 36% of Tie cancers and 51% TB lesions (P = NS). PSA-detected cancers were indistinguishable from palpable lesions by all measures evaluated. Prostate cancers detected in asymptomatic men by an elevated PSA should be considered biologically significant lesions. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:28 / 30
页数:3
相关论文
共 13 条
[1]   CANCER STATISTICS, 1994 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T ;
MONTGOMERY, S .
CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) :7-26
[2]   DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
BASLER, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08) :948-954
[3]   NERVE-SPARING RADICAL PROSTATECTOMY - EVALUATION OF RESULTS AFTER 250 PATIENTS [J].
CATALONA, WJ ;
BIGG, SW .
JOURNAL OF UROLOGY, 1990, 143 (03) :538-544
[4]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[5]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
[6]   THE USE OF PROSTATE-SPECIFIC ANTIGEN FOR PROSTATE-CANCER SCREENING - A MANAGED CARE PERSPECTIVE [J].
HANDLEY, MR ;
STUART, ME .
JOURNAL OF UROLOGY, 1994, 152 (05) :1689-1692
[7]   TRENDS IN PROSTATE-CANCER CARE IN THE UNITED-STATES, 1974-1990 - OBSERVATIONS FROM THE PATIENT-CARE EVALUATION STUDIES OF THE AMERICAN-COLLEGE-OF-SURGEONS-COMMISSION-ON-CANCER [J].
METTLIN, C ;
JONES, GW ;
MURPHY, GP .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (02) :83-91
[8]  
MUNCH H, 1991, CA, V41, P7
[9]  
OESTERLING JE, 1993, UROL CLIN N AM, V20, P687
[10]   THE USE OF PROSTATE-SPECIFIC ANTIGEN, CLINICAL STAGE AND GLEASON SCORE TO PREDICT PATHOLOGICAL STAGE IN MEN WITH LOCALIZED PROSTATE-CANCER [J].
PARTIN, AW ;
YOO, J ;
CARTER, HB ;
PEARSON, JD ;
CHAN, DW ;
EPSTEIN, JI ;
WALSH, PC .
JOURNAL OF UROLOGY, 1993, 150 (01) :110-114